Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity.

Hodroge A, Matagrin B, Moreau C, Fourel I, Hammed A, Benoit E, Lattard V.

J Thromb Haemost. 2012 Dec;10(12):2535-43. doi: 10.1111/jth.12019.

2.

Biochemical characterization of spontaneous mutants of rat VKORC1 involved in the resistance to antivitamin K anticoagulants.

Hodroge A, Longin-Sauvageon C, Fourel I, Benoit E, Lattard V.

Arch Biochem Biophys. 2011 Nov;515(1-2):14-20. doi: 10.1016/j.abb.2011.08.010. Epub 2011 Aug 31.

PMID:
21907178
3.

VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapy.

Hammed A, Matagrin B, Spohn G, Prouillac C, Benoit E, Lattard V.

J Biol Chem. 2013 Oct 4;288(40):28733-42. doi: 10.1074/jbc.M113.457119. Epub 2013 Aug 8.

4.

Structural Modeling Insights into Human VKORC1 Phenotypes.

Czogalla KJ, Watzka M, Oldenburg J.

Nutrients. 2015 Aug 14;7(8):6837-51. doi: 10.3390/nu7085313. Review.

5.

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].

Moreau C, Siguret V, Loriot MA.

Rev Med Interne. 2010 May;31(5):361-8. doi: 10.1016/j.revmed.2009.07.014. Epub 2010 Apr 1. French.

PMID:
20362363
6.

Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1.

Harrington DJ, Gorska R, Wheeler R, Davidson S, Murden S, Morse C, Shearer MJ, Mumford AD.

J Thromb Haemost. 2008 Oct;6(10):1663-70. doi: 10.1111/j.1538-7836.2008.03116.x. Epub 2008 Aug 1.

7.
8.

In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.

Nowak-Göttl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C, Mitchell LG.

Blood. 2010 Dec 23;116(26):6101-5. doi: 10.1182/blood-2010-05-283861. Epub 2010 Sep 10.

9.

A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.

Stepien E, Branicka A, Ciesla-Dul M, Undas A.

J Appl Genet. 2009;50(4):399-403. doi: 10.1007/BF03195700.

PMID:
19875892
10.

VKORC1 and the vitamin K cycle.

Garcia AA, Reitsma PH.

Vitam Horm. 2008;78:23-33. doi: 10.1016/S0083-6729(07)00002-7. Review.

PMID:
18374188
11.

Consequences of the Y139F Vkorc1 mutation on resistance to AVKs: in-vivo investigation in a 7th generation of congenic Y139F strain of rats.

Grandemange A, Kohn MH, Lasseur R, Longin-Sauvageon C, Berny P, Benoit E.

Pharmacogenet Genomics. 2009 Oct;19(10):742-50. doi: 10.1097/FPC.0b013e32832ee55b.

12.

Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle.

Oldenburg J, Bevans CG, Müller CR, Watzka M.

Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):347-53. Review.

PMID:
16677080
13.

[Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms].

Stępień E, Wypasek E, Branicka A, Undas A.

Kardiol Pol. 2010;68 Suppl 5:S428-35. Review. Polish.

PMID:
22134997
14.

[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].

Loriot MA, Beaune P.

Rev Med Interne. 2006 Dec;27(12):979-82. Epub 2006 Oct 11. Review. French.

PMID:
17070618
16.

A new cell culture-based assay quantifies vitamin K 2,3-epoxide reductase complex subunit 1 function and reveals warfarin resistance phenotypes not shown by the dithiothreitol-driven VKOR assay.

Fregin A, Czogalla KJ, Gansler J, Rost S, Taverna M, Watzka M, Bevans CG, Müller CR, Oldenburg J.

J Thromb Haemost. 2013 May;11(5):872-80. doi: 10.1111/jth.12185.

18.

Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.

Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD.

Thromb Haemost. 2005 Jan;93(1):23-6.

PMID:
15630486
19.

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.

Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J.

Nature. 2004 Feb 5;427(6974):537-41.

PMID:
14765194
20.

New insights into the catalytic mechanism of vitamin K epoxide reductase (VKORC1) - The catalytic properties of the major mutations of rVKORC1 explain the biological cost associated to mutations.

Matagrin B, Hodroge A, Montagut-Romans A, Andru J, Fourel I, Besse S, Benoit E, Lattard V.

FEBS Open Bio. 2013 Feb 16;3:144-50. doi: 10.1016/j.fob.2013.02.001. Print 2013.

Supplemental Content

Support Center